Evidence map›Paper›PMID 35448706›Full record

ArticleTomography (Ann Arbor, Mich.)2022

Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response.

Alex Anh-Tu Nguyen, Natsuko Onishi, Julia Carmona-Bozo, Wen Li, John Kornak, David C Newitt, Nola M Hylton

Open access · goldAbstract read
In one paragraph

Article in Tomography (Ann Arbor, Mich.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alex Anh-Tu NguyenDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5109-871X
Natsuko OnishiDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-4495-9187
Julia Carmona-BozoDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.
Wen LiDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-6584-363X
John KornakDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143, USA.
David C NewittDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.
Nola M HyltonDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.
University of California, San Francisco · US

Funding

The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nola M. Hylton-Watson · 2017 to 2026
$22.9M
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment TrialsR01CA132870 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M., NEWITT, DAVID C · 2008 to 2019
$4.8M
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapyR01CA227763 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Natsuko Onishi Yamashita · 2019 to 2026
$3.6M
Quantitative Imaging for Assessing Breast Cancer Response to TreatmentU01CA225427 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M. · 2018 to 2022
$3.2M
Quantitative Imaging for Assessing Breast Cancer Response to TreatmentU01CA151235 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M. · 2011 to 2015
$2.8M
NCI NIH HHS R01 CA227763NCI NIH HHS U01 CA225427NIH HHS P01 CA210961NIH HHS R01 CA132870NIH HHS U01 CA151235
6 · The paper itself

Abstract

Background parenchymal enhancement (BPE) of breast fibroglandular tissue (FGT) in dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has shown an association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Fully automated segmentation of FGT for BPE calculation is a challenge when image artifacts are present. Low spatial frequency intensity nonuniformity due to coil sensitivity variations is known as bias or inhomogeneity and can affect FGT segmentation and subsequent BPE measurement. In this study, we utilized the N4ITK algorithm for bias correction over a restricted bilateral breast volume and compared the contralateral FGT segmentations based on uncorrected and bias-corrected images in three MRI examinations at pre-treatment, early treatment and inter-regimen timepoints during NAC. A retrospective analysis of 2 cohorts was performed: one with 735 patients enrolled in the multi-center I-SPY 2 TRIAL and the sub-cohort of 340 patients meeting a high-quality benchmark for segmentation. Bias correction substantially increased the FGT segmentation quality for 6.3-8.0% of examinations, while it substantially decreased the quality for no examination. Our results showed improvement in segmentation quality and a small but statistically significant increase in the resulting BPE measurement after bias correction at all timepoints in both cohorts. Continuing studies are examining the effects on pCR prediction.

Indexed as

BreastBreast NeoplasmsFemaleHumansMagnetic Resonance ImagingNeoadjuvant TherapyRetrospective Studiesbackground parenchymal enhancementbias correctionbreast cancerbreast MRIneoadjuvant chemotherapy

Identifiers

PMID35448706
PMCPMC9027600
OpenAlexW4224325860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.